Syncom Formulations (India)
- P/E
- 22.84
Key Fundamentals
MicrocapPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of · EPS basis: Standalone · TTM
- ROCE
- 24.80%
- Debt to Equity
- 0.00
- EPS (TTM)
- ₹0.90
- Book Value
- ₹4.41
- Market Cap
- —
- P/E (TTM)
- 22.84
- P/B
- 4.66
- ROE
- 17.60%
- Dividend Yield
- 0.52%
- EBITDA
- ₹109 Cr
- 52W High
- ₹27.49
- 52W Low
- ₹10.21
- Day Range
- ₹18.95 – ₹20.69
- Volume
- 1,36,85,844
Peer Comparison
Healthcare › Pharmaceuticals
| ₹1,773.40 | 38.81 | ₹4,29,049 Cr | 4.77 | 0.90% | 16.00% | 20.50% | ₹61,631 Cr | ₹10,987 Cr | |
| ₹10,037.50 | 91.10 | ₹2,65,269 Cr | 15.90 | 0.30% | 16.50% | 22.00% | ₹11,230 Cr | ₹2,925 Cr | |
| ₹4,738.50 | 78.61 | ₹1,77,061 Cr | 9.81 | 0.82% | 27.40% | 15.20% | ₹17,400 Cr | ₹2,099 Cr | |
| ₹1,188.10 | 26.44 | ₹1,25,446 Cr | 4.37 | 0.08% | 21.20% | 21.10% | ₹28,592 Cr | ₹4,593 Cr | |
| ₹2,323.80 | 114.81 | ₹1,25,228 Cr | 20.72 | 0.04% | 18.30% | 17.80% | ₹7,270 Cr | ₹1,090 Cr | |
| ₹1,374.00 | 35.59 | ₹1,14,543 Cr | 2.96 | 0.58% | 11.20% | 13.00% | ₹33,228 Cr | ₹3,184 Cr | |
| ₹1,402.00 | 33.59 | ₹1,12,454 Cr | 3.20 | 0.93% | 11.60% | 15.50% | ₹28,324 Cr | ₹3,356 Cr | |
| Syncom Formulations (this company) | ₹20.56 | 22.84 | ₹1,849 Cr | 4.66 | 0.52% | 17.60% | 24.80% | ₹495 Cr | ₹86 Cr |
| Median 8 companies | ₹1,587.70 | 37.20 | ₹1,25,337 Cr | 4.72 | 0.55% | 17.05% | 19.15% | ₹22,862 Cr | ₹3,055 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 100/100
Category scores
- Quality
- 57
- Good
- Returns, margins, earnings quality 22% weight
- Valuation
- 71
- Strong
- Cheap vs sector & own history 24% weight
- Growth
- 12
- Poor
- Sales & profit trajectory 9% weight
- Financial Health
- 88
- Strong
- Solvency, leverage, coverage 9% weight
- Momentum
- 76
- Strong
- Trend strength, vol-adjusted 12% weight
- Ownership
- 66
- Strong
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
2- Company has reduced debt.
- Company is almost debt free.
Weaknesses
1- Earnings include an other income of Rs.32.8 Cr.
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Bullish | 5 | 6 | 8 |
| Oscillators | Bearish | 2 | 6 | 1 |
| Moving Averages | Strong Bullish | 3 | 0 | 7 |
Oscillators
Bearish
Overall
Bullish
Moving Averages
Strong Bullish
Key readings
- RSI (14)
- 48.35
- Neutral
- MACD (12,26,9)
- −0.40
- Bearish
- SMA (50)
- 20.82
- Bearish
- SMA (200)
- 15.35
- Bullish
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.
Revenue
| 10Y | +10.20% |
|---|---|
| 5Y | +14.68% |
| 3Y | +29.85% |
| 1Y | +5.42% |
| TTM | +0.41% |
Net profit
| 10Y | +22.48% |
|---|---|
| 5Y | +21.25% |
| 3Y | +56.05% |
| 1Y | +55.10% |
| TTM | +48.28% |
Operating cash flow
| 10Y | +9.22% |
|---|---|
| 5Y | Turned positive |
| 3Y | +79.67% |
| 1Y | +152.17% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | +6.60 pp |
|---|---|
| 5Y | +0.33 pp |
| 3Y | +6.83 pp |
| 1Y | +4.13 pp |
| TTM | +5.41 pp |
Revenue by year
| Mar 2017 | ₹185 Cr |
|---|---|
| Mar 2018 | ₹159 Cr |
| Mar 2019 | ₹187 Cr |
| Mar 2020 | ₹206 Cr |
| Mar 2021 | ₹245 Cr |
| Mar 2022 | ₹216 Cr |
| Mar 2023 | ₹222 Cr |
| Mar 2024 | ₹257 Cr |
| Mar 2025 | ₹461 Cr |
| Mar 2026 | ₹486 Cr |
Net profit by year
| Mar 2017 | ₹11.00 Cr |
|---|---|
| Mar 2018 | ₹9.00 Cr |
| Mar 2019 | ₹11.00 Cr |
| Mar 2020 | ₹14.00 Cr |
| Mar 2021 | ₹29.00 Cr |
| Mar 2022 | ₹20.00 Cr |
| Mar 2023 | ₹20.00 Cr |
| Mar 2024 | ₹24.00 Cr |
| Mar 2025 | ₹49.00 Cr |
| Mar 2026 | ₹76.00 Cr |
Quarterly Results
₹ Cr| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 59 | 62 | 63 | 73 | 87 | 101 | 127 | 148 | 117 | 121 | 115 | 134 | 125 |
| Expenses | 53 | 56 | 57 | 64 | 76 | 90 | 112 | 131 | 101 | 103 | 93 | 113 | 99 |
| Operating Profit | 6 | 6 | 7 | 9 | 10 | 12 | 15 | 17 | 16 | 19 | 21 | 21 | 26 |
| OPM % | 10% | 10% | 11% | 12% | 12% | 12% | 11% | 12% | 14% | 15% | 18% | 16% | 21% |
| Other Income | 2 | 4 | 4 | 3 | 1 | 4 | 4 | 7 | 6 | 5 | 5 | 14 | 8 |
| Interest | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 |
| PBT | 6 | 8 | 9 | 9 | 10 | 15 | 17 | 23 | 20 | 22 | 25 | 33 | 32 |
| Tax % | 27% | 24% | 25% | 27% | 24% | 25% | 24% | 24% | 22% | 25% | 25% | 25% | 23% |
| Net Profit | 4 | 6 | 6 | 7 | 8 | 11 | 13 | 18 | 16 | 17 | 19 | 25 | 25 |
| EPS (₹) | 0.05 | 0.07 | 0.07 | 0.07 | 0.08 | 0.12 | 0.14 | 0.19 | 0.17 | 0.18 | 0.2 | 0.26 | 0.26 |
Profit & Loss
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 173 | 184 | 185 | 159 | 187 | 206 | 245 | 216 | 222 | 257 | 461 | 487 | 495 |
| Expenses | 155 | 167 | 168 | 147 | 175 | 189 | 207 | 196 | 202 | 229 | 407 | 409 | 407 |
| Operating Profit | 18 | 17 | 16 | 12 | 12 | 17 | 38 | 20 | 20 | 28 | 54 | 77 | 87 |
| OPM % | 11% | 9% | 9% | 7% | 6% | 8% | 16% | 9% | 9% | 11% | 12% | 16% | 18% |
| Other Income | 1 | 3 | 3 | 4 | 5 | 5 | 7 | 12 | 15 | 13 | 17 | 31 | 33 |
| Interest | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 3 | 5 | 1 | 1 | 1 |
| Depreciation | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 7 | 7 |
| PBT | 16 | 16 | 16 | 12 | 13 | 17 | 41 | 26 | 27 | 32 | 65 | 101 | 112 |
| Tax % | 38% | 36% | 33% | 28% | 12% | 18% | 28% | 24% | 24% | 26% | 24% | 24% | — |
| Net Profit | 10 | 10 | 11 | 9 | 11 | 14 | 29 | 20 | 20 | 24 | 49 | 76 | 85 |
| EPS (₹) | 0.13 | 0.13 | 0.14 | 0.11 | 0.14 | 0.18 | 0.37 | 0.23 | 0.21 | 0.25 | 0.52 | 0.81 | 0.9 |
| Div. Payout % | 16% | 15% | 15% | 0% | 0% | 0% | 0% | 13% | 0% | 0% | 0% | 12% | — |
Balance Sheet
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 78 | 78 | 78 | 78 | 78 | 78 | 79 | 86 | 94 | 94 | 94 | 94 |
| Reserves | 22 | 31 | 36 | 44 | 55 | 68 | 109 | 136 | 162 | 192 | 246 | 318 |
| Borrowings | 6 | 6 | 12 | 12 | 9 | 2 | 62 | 58 | 83 | 72 | 4 | 1 |
| Other Liabilities | 31 | 61 | 48 | 37 | 32 | 33 | 42 | 28 | 38 | 33 | 66 | 116 |
| Total Liabilities | 138 | 175 | 175 | 171 | 173 | 181 | 292 | 308 | 377 | 392 | 410 | 529 |
| Fixed Assets | 46 | 46 | 85 | 89 | 89 | 93 | 91 | 94 | 91 | 120 | 125 | 184 |
| CWIP | 0 | 5 | 0 | 1 | 0 | 0 | 0 | 6 | 26 | 0 | 0 | 0 |
| Investments | 6 | 23 | 1 | 2 | 2 | 1 | 11 | 43 | 64 | 66 | 93 | 109 |
| Other Assets | 85 | 101 | 89 | 79 | 83 | 87 | 189 | 165 | 196 | 206 | 192 | 237 |
| Total Assets | 138 | 175 | 175 | 171 | 173 | 181 | 292 | 308 | 377 | 392 | 410 | 529 |
Cash Flow
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 0 | 24 | 17 | −2 | 4 | 6 | −2 | 16 | 10 | −6 | 23 | 58 |
| Investing | 1 | −23 | −8 | −2 | 2 | 2 | −75 | −27 | −45 | 84 | −18 | −51 |
| Financing | 1 | −2 | −2 | −2 | 0 | −7 | 72 | 8 | 35 | −15 | −68 | −3 |
| Net Cash Flow | 2 | −1 | 6 | −6 | 7 | 1 | −5 | −2 | 1 | 63 | −63 | 4 |
| Free Cash Flow | −3 | 16 | 9 | −8 | 10 | 4 | −5 | 5 | −10 | −14 | 13 | 47 |
| CFO/EBITDA | 32 | 176 | 128 | 13 | 66 | 61 | 24 | 113 | 86 | 6 | 70 | 105 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 66 | 91 | 91 | 87 | 81 | 77 | 112 | 114 | 124 | 132 | 85 | 81 |
| Inventory Days | 34 | 43 | 29 | 37 | 37 | 39 | 51 | 51 | 53 | 49 | 49 | 81 |
| Days Payable | 63 | 130 | 92 | 75 | 57 | 49 | 66 | 36 | 52 | 33 | 52 | 96 |
| Cash Conversion Cycle | 37 | 4 | 27 | 49 | 61 | 67 | 96 | 129 | 124 | 148 | 81 | 66 |
| Working Capital Days | 84 | 40 | 45 | 75 | 74 | 88 | 28 | 33 | −4 | 51 | 95 | 85 |
| ROCE % | 16% | 15% | 14% | 9% | 9% | 12% | 21% | 11% | 10% | 10% | 19% | 25% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Syncom Formulations insights
63 extracted metrics across FY11–FY27.
Documents
- 8 Aug 2025
- General announcements 8 Oct 2026
Frequently Asked Questions about Syncom Formulations (India)
What does Syncom Formulations (India) Ltd do?
Where is Syncom Formulations (India) Ltd (SYNCOMF) listed?
Which sector does Syncom Formulations (India) Ltd belong to?
What is the PE ratio of Syncom Formulations (India) Ltd?
What is the 52-week high and low of Syncom Formulations (India) Ltd?
Does Syncom Formulations (India) Ltd pay dividends?
What is the Return on Equity (ROE) of Syncom Formulations (India) Ltd?
Company Information
Established in the year 1995, Syncom Formulations is a global pharmaceutical company that manufactures and markets a broad range of healthcare products. The company is a generic pharmaceutical player operating in more than 15 countries worldwide having more than 400 products registered.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/SYNCOMF.md for Syncom Formulations (India) Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.